ASH 2024: Priority Report: Updates in Myeloproliferative Neoplasms

home / publications / supplements / ash-2024-priority-report-updates-in-myeloproliferative-neoplasms

Experts detail updates in myeloproliferative neoplasms from the 2024 ASH Annual Meeting & Exposition.

Momelotinib in Myelofibrosis | Image Credit: © Fotograf – stock.adobe.com

MAIC Points to Improved OS With Momelotinib in Ruxolitinib-Pretreated Myelofibrosis

Caroline Seymour;Kyle Doherty
December 13th 2024
Article

Momelotinib improved OS vs best available therapy in patients with ruxolitinib-experienced myelofibrosis, according to data from a MAIC analysis.

Jeremy DiGennaro, MD, internal medicine resident physician at the University of South Florida Morsani College of Medicine

Pacritinib and Momelotinib Display Positive Real-World Impact on Anemia and Transfusion Needs in Myelofibrosis

Kyle Doherty
December 12th 2024
Article

Pacritinib and momelotinib both demonstrated favorable real-world effects on anemia and transfusion requirements among patients with myelofibrosis.

Myelofibrosis

Momelotinib Shows Real-World Improvements in Anemia, Symptoms, and Spleen Response in Myelofibrosis

Courtney Flaherty
December 12th 2024
Article

Real-world treatment with momelotinib led to high transfusion independence rates among patients with JAK inhibitor–exposed and –naive myelofibrosis.

Myelofibrosis | Image Credit: © Tatiana Shepeleva – stock.adobe.com

Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis

Morgan Bayer
December 11th 2024
Article

Selinexor plus ruxolitinib showed activity in patients with myelofibrosis who were treated with ruxolitinib.

Myelofibrosis Navetemadlin

Navtemadlin Reduces Spleen Size and Symptom Score in R/R Myelofibrosis

Alex Biese
December 10th 2024
Article

Navtemadlin monotherapy was safe and effective among patients with myelofibrosis who were relapsed or refractory to treatment with JAK inhibitors.

ASH Meeting | Image credit: ©Nittaya – stock.adobe.com

Pelabresib Plus Ruxolitinib Leads to Sustained Responses in JAK Inhibitor–Naive Myelofibrosis

Jonah Feldman
December 9th 2024
Article

Improvements in the 4 hallmarks of myelofibrosis were observed with pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor-naive disease.